Physician profile
Diego Lim
NPI 1699038505
$2,449.37
in general payments reported to CMS, 2019-2025
22 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $107 · 2021: $233 · 2022: $287 · 2023: $1,049 · 2024: $125 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $639.29 | 2019-2025 | |
| Lucid Diagnostics INC. | $295.37 | 2023 | |
| Genzyme Corporation | $247.89 | 2022-2023 | |
| Endogastric Solutions, INC | $174.74 | 2021-2023 | Esophyx |
| Conmed Corporation | $150.23 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $127.53 | 2023 | Zeposia |
| Ardelyx, INC. | $125.00 | 2024 | Ibsrela |
| Janssen Scientific Affairs, LLC | $121.86 | 2025 | Tremfya |
| Enterra Medical, INC. | $88.32 | 2023 | |
| Pfizer INC. | $87.14 | 2019-2023 | |
| Cook Medical LLC | $69.04 | 2023 | Echotip |
| Ambu INC. | $63.93 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.50 | 2022-2023 | Gattex |
| Ferring Pharmaceuticals INC. | $42.75 | 2022 | |
| Shionogi INC | $33.09 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $27.64 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $23.20 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.04 | 2019 | |
| Janssen Biotech, INC. | $19.67 | 2023 | Stelara |
| Ipsen Biopharmaceuticals, INC | $16.32 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $16.21 | 2023 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.